Neurology: Volume 100, Number 5, January 31, 2023 Exam #2 - Ticagrelor Aspirin vs Clopidogrel Aspirin in CYP2C19 Loss-of-Function Carriers With Minor Stroke or TIA Stratified by Risk Profile

About this course

  • Released: 01/31/2023
  • Expires: 01/31/2026

 

TICAGRELOR ASPIRIN VS CLOPIDOGREL ASPIRIN IN CYP2C19 LOSS-OF-FUNCTION CARRIERS WITH MINOR STROKE OR TIA STRATIFIED BY RISK PROFILE

LEARNING OBJECTIVES:

Upon completion of the article by Wang et al, the participant should be able to:

  • State the degree of stroke risk reduction seen among CYP2C19 loss-of-function (LOF) carriers deemed at low risk for stroke who were treated with ticagrelor aspirin compared with clopidogrel aspirin in this study
  • Describe how 90-day stroke risk differed between among CYP2C19 LOF carriers deemed at high risk for stroke treated with ticagrelor aspirin vs those treated with clopidogrel aspirin in this study
  • Discuss how bleeding risks differed among CYP2C19 LOF carriers based on stroke risk and treatment assignment (ticagrelor aspirin vs clopidogrel aspirin) in this study

CORE COMPETENCIES:

The article by Wang et al covers the following core competency:
  • Medical knowledge

AUTHOR DISCLOSURES:

Refer to Information and Author section available in the Tool Bar for each article.

 

THIS PAGE IS REQUIRED READING BEFORE BEGINNING ALL ACCME-ACCREDITED COURSES

ACCREDITATION STATEMENT

The American Academy of Neurology Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

MISSION STATEMENT/PROGRAM OBJECTIVES

After evaluating a specific article published in Neurology, participants in the CME activity should be able to demonstrate an increase in, or affirmation of, their knowledge of clinical medicine. Participants should be able to evaluate the appropriateness of the clinical information as it applies to the provision of patient care.

PARTICIPANTS

This program is designed for physicians who are involved in providing patient care and who wish to advance their current knowledge of clinical medicine.

AMA CREDIT DESIGNATION STATEMENT

The American Academy of Neurology Institute designates this journal-based-CME activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DISCLOSURES

CME Journal Editors: James W.M. Owens, Jr., MD, PhD: Scientific Advisory Boards: Member of data safety monitoring board, RaSURE study, AADi Bioscience, Inc. Funding for travel or speaker honoraria: Honoraria, Program Director, AAN Annual Meeting. Editorial Boards: CME Editor, Neurology and Adam Kelly, MD: Editorial Boards: Neurology, CME editor, ongoing since January 2016. Other activities: Question writing for American Academy of Neurology activities, including Continuum. AAN staff members editing the test (K. Aman Ramm) have no disclosures. All relevant financial relationships have been mitigated.

COMMERCIAL SUPPORT

This CME program receives no commercial support.

ACCME